Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15398137 | 0.96 | THRA (0.41) | THRATHRBTSHRHPGDHTT | |
| SCHEMBL12604125 | 0.94 | NPC1 (0.40) | THRATHRBTSHRHPGDHTT | |
| SCHEMBL816966 | 0.94 | NPC1 (0.40) | THRATHRBTSHRHPGDHTT | |
| SCHEMBL12733655 | 0.94 | THRA (0.39) | THRAHPGDALDH1A1CA12CA9 | |
| SCHEMBL816039 | 0.93 | NPC1 (0.41) | THRATHRBTSHRHPGDHTT | |
| SCHEMBL815903 | 0.93 | NPC1 (0.41) | THRATHRBTSHRHPGDHTT | |
| SCHEMBL12604071 | 0.92 | NPC1 (0.40) | THRBTSHRHPGDHTTCYP3A4 | |
| SCHEMBL15398086 | 0.91 | NPC1 (0.39) | THRBTSHRHPGDHTTCYP3A4 | |
| SCHEMBL816854 | 0.90 | MAPT (0.36) | TSHRHPGDCA12CA9 | |
| SCHEMBL19757256 | 0.90 | THRB (0.42) | THRATHRBTSHRHPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325168-B1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORP (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2325168-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | Adeka Corporation (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | H1-4, XPO4, F12 | THRA 4622/4885THRB 4794/4885TSHR 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.